产品
编 号：F504690
分子式：C20H20N2O2
分子量：320.39
分子式：C20H20N2O2
分子量：320.39
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
280
In-stock
5mg
616
In-stock
10mg
1000
In-stock
50mg
3440
In-stock
100mg
6160
In-stock
结构图
CAS No: 892711-75-0
产品详情
生物活性：
CDN1163 is an allosteric sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activator that improves Ca2+ homeostasis. CDN1163 attenuates diabetes and metabolic disorders.
体内研究：
CDN1163 (50 mg/kg; intraperitoneal injection; for 5 days; male ob/ob mice and lean ob/+ mice) increases SERCA2 Ca2+-ATPase activity, decreases endoplasmic reticulum (ER) stress-induced cell death in vitro and improves liver Ca2+ transport activity. CDN1163 reduces blood glucose levels and improves metabolic parameters and gluconeogenic gene expression, reverses hepatic steatosis, inhibits ER stress and ER stress-induced apoptosis, and improves mitochondrial efficiency in ob/ob mice in vivo.Animal Model:Male 8-10-week old ob/ob mice and lean ob/+ mice
Dosage:50 mg/kg
Administration:Intraperitoneal injection; for 5 days
Result:Markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis but did not alter glucose levels or body weight. Increased expression of uncoupling protein 1 (UCP1) and UCP3 in brown adipose tissue and reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis, possibly through SERCA2-mediated activation of AMP-activated protein kinase pathway.
体外研究：
CDN1163 (10?μM; 24 hours; rat cardiac myocyte cells) treatment reduces high glucose-induced resistin and nuclear NFATc expression and increases the phosphorylation of AMPKα in a time-dependent manner.
CDN1163 is an allosteric sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activator that improves Ca2+ homeostasis. CDN1163 attenuates diabetes and metabolic disorders.
体内研究：
CDN1163 (50 mg/kg; intraperitoneal injection; for 5 days; male ob/ob mice and lean ob/+ mice) increases SERCA2 Ca2+-ATPase activity, decreases endoplasmic reticulum (ER) stress-induced cell death in vitro and improves liver Ca2+ transport activity. CDN1163 reduces blood glucose levels and improves metabolic parameters and gluconeogenic gene expression, reverses hepatic steatosis, inhibits ER stress and ER stress-induced apoptosis, and improves mitochondrial efficiency in ob/ob mice in vivo.Animal Model:Male 8-10-week old ob/ob mice and lean ob/+ mice
Dosage:50 mg/kg
Administration:Intraperitoneal injection; for 5 days
Result:Markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis but did not alter glucose levels or body weight. Increased expression of uncoupling protein 1 (UCP1) and UCP3 in brown adipose tissue and reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis, possibly through SERCA2-mediated activation of AMP-activated protein kinase pathway.
体外研究：
CDN1163 (10?μM; 24 hours; rat cardiac myocyte cells) treatment reduces high glucose-induced resistin and nuclear NFATc expression and increases the phosphorylation of AMPKα in a time-dependent manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备